Skip to main content
Clinical Trials/NCT06549218
NCT06549218
Recruiting
N/A

Shortening the Path to Rare Disease Diagnosis by Using Newborn Genetic Screening and Digital Technologies (SCREEN4CARE): Genetic Newborn Screening for Rare Diseases Within the Screen4Care Project

University Hospital Freiburg6 sites in 3 countries20,000 target enrollmentDecember 3, 2024

Overview

Phase
N/A
Intervention
Not specified
Conditions
Newborn Screening
Sponsor
University Hospital Freiburg
Enrollment
20000
Locations
6
Primary Endpoint
TREAT-panel
Status
Recruiting
Last Updated
9 months ago

Overview

Brief Summary

The main objective of the genetic newborn screening part of the Screen4Care-project is to shorten the path to rare disease diagnosis and to facilitate early intervention. Therefore, genetic newborn screening for currently treatable rare diseases (TREAT-panel approach) will be offered to families expecting a baby. Whole genome sequencing (WGS) will be offered as additional diagnostic approach to newborns participating in Screen4Care TREAT-panel approach, if they develop symptoms suggestive of a genetic disease.

To evaluate to what extend genetic newborn screening has an impact on participating infants and their families, a follow-up with standardised questionnaires will be performed for all participating families.

Registry
clinicaltrials.gov
Start Date
December 3, 2024
End Date
December 1, 2025
Last Updated
9 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
University Hospital Freiburg
Responsible Party
Principal Investigator
Principal Investigator

Jan Kirschner

Prof. Dr.

University Hospital Freiburg

Eligibility Criteria

Inclusion Criteria

  • TREAT-panel:
  • Infants born in one of the participating hospitals and birth centres
  • Informed consent signed by both parents/legal guardian to participate in genetic newborn screening (TREAT-panel)
  • Whole genome sequencing:
  • Participation in the TREAT-panel study
  • Symptoms suggestive of a genetic disease within the first 2 years of life
  • Informed consent signed by both parents/legal guardian to participate in genetic newborn screening (TREAT-panel) and the whole genome sequencing

Exclusion Criteria

  • Missing informed consent of parents/legal guardian

Outcomes

Primary Outcomes

TREAT-panel

Time Frame: 1 year

• Percentage of infants in whom pathogenic or likely pathogenic variants that predict one of the target diseases will be identified

Whole Genome Sequencing

Time Frame: 2 years

• Percentage of infants where genetic diagnosis is achieved by whole genome sequencing

Secondary Outcomes

  • TREAT-panel(1 year)
  • Whole Genome Sequencing(2 years)

Study Sites (6)

Loading locations...

Similar Trials